Literature DB >> 6353568

IgA antibodies to Klebsiella pneumoniae in ankylosing spondylitis.

A K Trull, R Ebringer, G S Panayi, D Colthorpe, D C James, A Ebringer.   

Abstract

Serum IgA antibodies to Klebsiella pneumoniae were measured in 65 patients with ankylosing spondylitis (AS) during different phases of disease activity and compared with the antibody level in 21 psoriatic arthritis (PsA) patients, 43 rheumatoid arthritis (RA) patients and 57 healthy controls. The mean IgA antibody to Klebsiella in AS patients with an erythrocyte sedimentation rate (ESR) greater than or equal to 15 mm/h was significantly higher than the antibody level in patients with an ESR less than 15 mm/h (p less than 0.02) and tended to increase with rising ESR. There was a significant difference in anti-Klebsiella antibody levels between AS patients with an elevated ESR and antibody levels in PsA patients (p less than 0.001), RA patients (p less than 0.001) and healthy controls (p less than 0.005). There was no difference between healthy controls and patients with PsA, RA or AS patients with a low ESR. The IgA anti-Klebsiella antibody was specifically absorbed out from sera with inactivated klebsiella pneumoniae organisms. Antibody levels to Candida albicans and Escherichia coli did not differ in patients vis-à-vis control subjects. The mean serum anti-Klebsiella IgA level was found to be higher in patients who were either clinically active or had positive faeval cultures, when compared with patients with inactive disease and negative cultures, but these differences were not statistically significant, although when both parameters were examined together a significant additive effect was detected (p less than 0.001). It is concluded that patient with AS exhibit a specific elevation of serum IgA antibody to Klebsiella antigen.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6353568     DOI: 10.3109/03009748309098543

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  32 in total

Review 1.  [Rheumatology update. Current knowledge of etiology, pathophysiology, diagnosis, and therapy of selected arthritic disorders. Part I: pathogenesis and differential diagnosis].

Authors:  G Hein; P Oelzner; H Sprott; B Manger
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 2.  Small intestinal mucosal protection mechanisms and their importance in rheumatology.

Authors:  S O'Mahony; A Ferguson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

3.  Antibody to a 63 kilodalton insect protein in ankylosing spondylitis.

Authors:  S R Brand; J Worthington; D P McIntosh; R M Bernstein
Journal:  Ann Rheum Dis       Date:  1992-03       Impact factor: 19.103

Review 4.  HLA-B27 and bacteria.

Authors:  J Uksila; P Toivanen
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

Review 5.  Clinical, bacteriological, and serological aspects of Klebsiella infections and their spondylarthropathic sequelae.

Authors:  H Sahly; R Podschun
Journal:  Clin Diagn Lab Immunol       Date:  1997-07

6.  Ig A antibodies to klebsiella in ankylosing spondylitis.

Authors:  O Ardiçoğlu; M B Atay; H Ataoğlu; N Etiz; H Ozenci
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

7.  Ankylosing spondylitis, HLA-B27, and klebsiella: cross reactivity and antibody studies.

Authors:  A Ebringer; M Ghuloom
Journal:  Ann Rheum Dis       Date:  1986-08       Impact factor: 19.103

8.  Immune complexes in ankylosing spondylitis.

Authors:  I L MacLean; J R Archer; M I Cawley; B L Kidd; B P O'Hara; F S Pegley; P W Thompson
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

9.  IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis.

Authors:  K Granfors; A Toivanen
Journal:  Ann Rheum Dis       Date:  1986-07       Impact factor: 19.103

10.  Correlation of immunoglobulin and C reactive protein levels in ankylosing spondylitis and rheumatoid arthritis.

Authors:  K M Sanders; A Hertzman; M R Escobar; B H Littman
Journal:  Ann Rheum Dis       Date:  1987-04       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.